Parenteral Drugs (India) Ltd.
NSE: PDPL | BSE: 524689
₹2.90
₹0.05
(1.75%)
As on 21-Aug-2023IST
Market cap
₹10 Cr
Revenue (TTM)
₹9 Cr
P/E Ratio
--
P/B Ratio
-0
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹-76 Cr
-
ROE
0 %
-
ROCE
0 %
-
Industry P/E
34.45
-
EV/EBITDA
-43.2
-
Debt to Equity
-0.1
-
Book Value
₹--
-
EPS
₹-47.3
-
Face value
10
-
Shares outstanding
29,816,300
10 Years Aggregate
CFO
₹867.64 Cr
EBITDA
₹-165.15 Cr
Net Profit
₹-1,003.91 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Parenteral Drugs
| -28.4 | -4.9 | -7.9 | -- | -- | -21.9 | -24.9 |
|
BSE Healthcare*
| 8.2 | 1.0 | 8.3 | 8.0 | 24.8 | 13.5 | 12.1 |
|
Company
|
2022
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|
|
Parenteral Drugs
| 6.6 | -58.0 | -65.1 | 15.1 | -60.7 |
|
BSE Small Cap
| -1.8 | -6.8 | -23.4 | 59.6 | 1.8 |
|
BSE Healthcare
| -12.1 | -3.5 | -5.9 | 0.5 | -12.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsNews & Analysis
All News
Pledging Gamble Sours for these Companies
2 min read•By Vikas Vardhan
About Parenteral Drugs
Parenteral Drugs (India) Limited operates as a healthcare company in India. The company manufactures pharmaceutical products, including intravenous infusion, inhalation, veterinary infusion, etc. It also offers IV fluids, such as carbohydrates and... electrolytes, diuretics, dialysis and irrigation solutions, anti-infective and anti-fungal products, and others; and oncology and anaesthesia products. The company also exports its products to Iraq, Yemen, Mozambique, Ghana, Kenya, Kyrgyzstan, Uzbekistan, Sudan, Vietnam, Cambodia, Liberia, Sri Lanka, Nepal, Myanmar, and Cameroon. The company was incorporated in 1983 and is based in Indore, India. Read more
-
Incorporated
1983
-
Chairman
Manohar Lal Gupta
-
Managing Director
Vinod Kumar Gupta
-
Headquarters
Mumbai, Maharashtra
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
FAQs for Parenteral Drugs
What is the current share price of Parenteral Drugs (India) Ltd Today?
The share price of Parenteral Drugs (India) Ltd is ₹2.90 (NSE) and ₹3.39 (BSE) as of 21-Aug-2023 IST. Parenteral Drugs (India) Ltd has given a return of --% in the last 1 years.
What is the current PB & PE ratio of Parenteral Drugs (India) Ltd?
Since, TTM earnings of Parenteral Drugs (India) Ltd is negative, P/E ratio is not available.
The P/B ratio of Parenteral Drugs (India) Ltd is -0.01 times as on 21-Aug-2023, a 100 discount to its peers’ median range of 4.78 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
0.00
|
-0.01
|
|
2020
|
0.00
|
-0.01
|
|
2019
|
0.00
|
-0.05
|
|
2018
|
0.00
|
-0.12
|
|
2017
|
0.00
|
-0.29
|
What is the 52 Week High and Low of Parenteral Drugs (India) Ltd?
The 52-week high and low of Parenteral Drugs (India) Ltd are Rs -- and Rs -- as of 10-Jun-2026.
What is the market cap of Parenteral Drugs (India) Ltd?
Parenteral Drugs (India) Ltd has a market capitalisation of ₹ 10 Cr as on 21-Aug-2023. As per SEBI classification, it is a Small Cap company.
Should I invest in Parenteral Drugs (India) Ltd?
Before investing in Parenteral Drugs (India) Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.